Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
101M
-
Number of holders
-
124
-
Total 13F shares, excl. options
-
77.3M
-
Shares change
-
-2.02M
-
Total reported value, excl. options
-
$949M
-
Value change
-
-$24.3M
-
Put/Call ratio
-
2.14
-
Number of buys
-
64
-
Number of sells
-
-55
-
Price
-
$12.27
Significant Holders of Day One Biopharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (DAWN) as of Q3 2023
155 filings reported holding DAWN - Day One Biopharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q3 2023.
Day One Biopharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (DAWN) has 124 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 77.3M shares
of 101M outstanding shares and own 76.35% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (7.81M shares), Atlas Venture Life Science Advisors, LLC (7.61M shares), FMR LLC (6.03M shares), BlackRock Inc. (4.69M shares), VANGUARD GROUP INC (4.63M shares), FRANKLIN RESOURCES INC (4.07M shares), BRAIDWELL LP (3.72M shares), STATE STREET CORP (2.94M shares), VIKING GLOBAL INVESTORS LP (2.56M shares), and Canaan Partners XI LLC (2.49M shares).
This table shows the top 124 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.